Ironwood Pharmaceuticals (IRWD +1%) gives a Q4 business update on the commercial launch of its...

|About: Ironwood Pharmaceuticals, Inc. (IRWD)|By:, SA News Editor

Ironwood Pharmaceuticals (IRWD +1%) gives a Q4 business update on the commercial launch of its irritable bowel syndrome Linzess in the U.S., saying its partner, Forest Laboratories (FRX) reported Q4 product sales of $19.2M. The company also said another commercial partner, Almirall, received approval for Constella for the treatment of moderate to severe irritable bowel syndrome in the European Union. Commercial launch will be initiated in the first half of FY13.